HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) with a maintained price target of $8.
May 09, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Karyopharm Therapeutics with a maintained $8 price target.
The reiteration of a Buy rating and maintenance of the price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100